We are pleased to share news from FSMA that they have announced funding of an industrial research programme at Cambria Biosciences to identify novel therapeutic targets for SMA. The focus of the research will be to search for genes that can alleviate the problems with defects in SMN1 using the roundworm Caenorhabditis elegans or C. elegans, which is a very powerful model organism that is widely used by scientists to identify novel genetic interactions:
Families of SMA is very excited to announce the first industrial grant awarded through our yearly grant application program for basic research. Cambria Biosciences approached Families of SMA about utilizing its expertise in applied genetic research to examine possible new treatment options for SMA.
Families of SMA awarded the grant to lead researcher Dr. Beth Westlund of Cambria as part of an ongoing commitment to funding the most promising research in the field of Spinal Muscular Atrophy. We are very excited about the opportunity to partner with this industrial leader in neurological disorder research.
For a complete copy of the news release issued click on: http://www.curesma.org/cambria06.shtml
Thank you for your continued support that allows us fund important research such as this project.
Together we will find a cure!
Families of Spinal Muscular Atrophy
www.CureSMA.org
